NovoCure Limited (NVCR)
(Real Time Quote from BATS)
$17.89 USD
-0.01 (-0.06%)
Updated Aug 19, 2024 03:38 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Income Statements
Fiscal Year end for NovoCure Limited falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 509 | 538 | 535 | 494 | 351 |
Cost Of Goods | 128 | 115 | 115 | 107 | 89 |
Gross Profit | 381 | 423 | 420 | 388 | 263 |
Selling & Adminstrative & Depr. & Amort Expenses | 614 | 513 | 464 | 357 | 264 |
Income After Depreciation & Amortization | -233 | -90 | -44 | 30 | -1 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | -41 | -8 | 8 | 12 | 8 |
Pretax Income | -192 | -82 | -52 | 18 | -9 |
Income Taxes | 15 | 11 | 6 | -2 | -2 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -207 | -93 | -58 | 20 | -7 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -207 | -93 | -58 | 20 | -7 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -245 | -80 | -31 | 43 | 5 |
Depreciation & Amortization (Cash Flow) | -12 | 9 | 13 | 12 | 6 |
Income After Depreciation & Amortization | -233 | -90 | -44 | 30 | -1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 106.39 | 104.66 | 103.43 | 108.88 | 97.24 |
Diluted EPS Before Non-Recurring Items | -1.95 | -0.88 | -0.56 | 0.18 | -0.07 |
Diluted Net EPS (GAAP) | -1.95 | -0.88 | -0.56 | 0.20 | -0.07 |
Fiscal Year end for NovoCure Limited falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 150.36 | 138.50 | 133.78 | 127.32 | 126.05 |
Cost Of Goods | 34.65 | 33.69 | 32.56 | 32.09 | 34.02 |
Gross Profit | 115.70 | 104.81 | 101.23 | 95.23 | 92.03 |
SG&A, R&D, and Dept/Amort Expenses | 149.29 | 146.34 | 152.95 | 153.47 | 154.70 |
Income After SG&A, R&D, and Dept/Amort Expenses | -33.59 | -41.53 | -51.72 | -58.24 | -62.67 |
Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | -10.85 | -9.88 | -13.18 | -10.02 | -8.76 |
Pretax Income | -22.73 | -31.64 | -38.53 | -48.22 | -53.90 |
Income Taxes | 10.65 | 7.12 | 8.55 | 1.26 | 3.51 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -33.38 | -38.76 | -47.08 | -49.49 | -57.42 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -33.38 | -38.76 | -47.08 | -49.49 | -57.42 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 107.70 | 107.27 | 106.98 | 106.77 | 106.29 |
Diluted EPS Before Non-Recurring Items | -0.31 | -0.36 | -0.45 | -0.46 | -0.54 |
Diluted Net EPS (GAAP) | -0.31 | -0.36 | -0.45 | -0.46 | -0.54 |